Kemp, Peter Button Background and Aims: Prevalence of nonalcoholic fatty liver disease (NAFLD) is higher in individuals with HIV infection than in the general population. The prevalence of metabolic syndrome in this population is rising. Limited data exists about the clinical and pathologic characteristics selleckchem of patients with HIV and NAFLD, and whether NAFLD in this population differs in clinical

presentation and severity of liver histology from primary NAFLD. Therefore, we aimed to examine the differences between HIV associated NAFLD and primary NAFLD. Methods: This is a cross-sectional analysis of a nested case-control study. All HIV infected patients without viral hepatitis, heavy alcohol use or other identifiable causes of liver disease were identified from a database of consecutive liver biopsies performed at the University of Selumetinib datasheet California, San Diego, over a 13 year period. Those with NAFLD were age and sex matched to

primary NAFLD controls who were randomly selected from the same pathology database. Clinical and biochemical data was collected through chart review. All patients underwent a standardized, detailed liver histologic research evaluation by a pathologist who was blinded to clinical and case/control status. Results: Of the 86 patients with HIV, without viral hepatitis who underwent liver biopsy, 33 (38%) had NAFLD. Most were receiving antiretroviral therapy (94%) with mean CD4 613 cells/uL. The case and control groups were similar for age, sex, metabolic risk factors and body mass index (BMI). Compared to primary NAFLD, patients with HIV associated NAFLD had significantly higher mean AST (88 vs 41, p <0.001), ALT (146 vs 62, p <0.001), alkaline phosphatase (141 vs 75, p=0.003, as well as significantly higher

triglyceride levels (242 vs 182, p=0.02). HIV infected patients were more likely to have definite steatohepatitis find more (62.7% vs 36.5%, p = 0.04) and higher NAFLD activity score (NAS) (mean 4.24 vs 3.33, p=.007). They were also more likely to have other features of significant disease, with more lobular inflammation and acidophil bodies (p<0.001 and 0.004 respectively). Conclusion: HIV infected patients are more likely to have higher liver enzymes, higher NAS score, increased presence of nonalcoholic steatohepatitis (NASH) than patients with primary NAFLD who have similar age, sex, BMI, and metabolic risk factors. Given more severe disease, this population should be considered for earlier testing and consideration of treatment. Disclosures: Rohit Loomba – Consulting: Gilead Inc, Corgenix Inc, Janssen and Janssen Inc; Grant/Research Support: Daiichi Sankyo Inc, AGA, Merck Inc The following people have nothing to disclose: Irine Vodkin, Mark A. Valasek, Ricki Bettencourt, Edward R. Cachay Introduction: Non-alcoholic fatty liver disease (NAFLD) is closely associated with central adiposity and the metabolic syndrome.